Tromsø, Norway, June 16th, 2025 – ArcticZymes Technologies ASA (OSE:AZT) is pleased to announce the expansion of its GMP product range, with the introduction of M-SAN HQ GMP, a new GMP grade nuclease specifically designed for viral vector manufacturing.
This new product combines the proven performance of M-SAN HQ with the regulatory robustness of GMP manufacturing, providing a highly effective solution for enzymatic host cell DNA removal under physiological salt conditions.
Unlike traditional nucleases, M-SAN HQ retains high activity at physiological salt concentrations (~150 mM), enabling direct use in cell culture media or harvest supernatants without harsh buffer exchanges. This makes it well-suited for the manufacture of fragile viral vectors such as lentiviruses and retroviruses, which are critical components of many advanced therapies and vaccine platforms.
With the launch of M-SAN HQ GMP, viral vector manufacturers can now benefit from the unmatched performance of M-SAN HQ, while ensuring a seamless transition into full-scale production.
With the emergence of new therapeutic strategies, such as in vivo CAR-T, the need to reduce nuclease and host cell DNA contamination in the final product is even more critical. M-SAN HQ GMP is perfectly positioned to answer this need, supporting the therapies of the future.
CEO Michael B. Akoh comments:
“With the launch of M-SAN HQ GMP, we’re bringing an important new product to the market—an enzyme that performs optimally under physiological salt conditions and meets GMP requirements, ensuring companies can quickly and easily move from product development into full scale production.
This new product is a direct response to customer needs for technically advanced and compliant nuclease that fit seamlessly into demanding biomanufacturing workflows. It demonstrates ArcticZymes’ ongoing commitment to enabling the success of advanced therapeutic developers.”
M-SAN HQ GMP will be available to ordering from June 16th, 2025
About ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.
Its headquarters are based in Tromsø, Norway, at the SIVA Science Park.
ArcticZymes Technologies’ IP and capabilities are protected via a large portfolio of patents.
For more information, please visit the website: www.arcticzymes.com
